Use these selected concepts to connect microscopic findings with clinical histories, imaging and disease mechanisms. The guide is intended for oral and maxillofacial pathology residents preparing for the American Academy of Oral and Maxillofacial Pathology (AAOMP) Fellowship Examination, whose stated difficulty reflects the midpoint of specialty training.
Adaptive immunity and antibody mechanisms
1. Specificity and the secondary immune response
Adaptive immune memory produces a faster, stronger antibody and cellular response when the same antigen is encountered again, because memory cells generated during the primary response are reactivated rapidly. This memory, however, is antigen-specific: exposure to one pathogen does not establish protection against unrelated pathogens, since the secondary response remains directed only at the original antigen's epitopes.
Worked example: In a laboratory animal, reinjection of antigen A weeks after primary immunization triggers a rapid, high-titer antibody response, demonstrating memory for A alone; a simultaneous first exposure to unrelated antigen B still produces only a slow primary response.
Mistake to avoid: Assuming that recovery from one viral infection confers protective memory against unrelated viruses, such as expecting varicella-zoster immunity to prevent measles.
Supporting reference: [16]
2. Humoral versus cell-mediated immunity
Humoral immunity comprises the mechanisms in which B cells mature in the bone marrow and produce antibodies that defend against extracellular pathogens and toxins. Cell-mediated immunity comprises T-cell functions; T cells, which mature in the thymus, orchestrate innate and adaptive responses and destroy host cells infected with intracellular pathogens. The categories describe mechanisms, not mutually exclusive responses to any infection.
Worked example: An antibody neutralizing a circulating bacterial toxin illustrates humoral immunity, while a cytotoxic T cell killing a host cell harboring replicating virus illustrates cell-mediated immunity; a single infection may engage both arms concurrently rather than activating only one.
Mistake to avoid: Labeling any immune response that involves a cell as cell-mediated immunity, overlooking that B cells participate in humoral responses.
Supporting reference: [16]
3. Antigens and their individual epitopes
Antibodies recognize small exposed surface regions of an antigen, called epitopes, rather than the entire molecule. A single antigen may possess several different epitopes, so different antibodies can bind different regions of the same antigen; multiple epitopes do not make one molecule multiple antigens.
Worked example: Two monoclonal antibodies raised against one recombinant protein each bind a different exposed surface loop; their distinct binding sites reflect separate epitopes on a single antigenic molecule, not two separate antigens.
Mistake to avoid: Assuming every antibody binding a given antigen recognizes the same epitope rather than one of several distinct regions.
Supporting reference: [16]
4. Haptens require a carrier to elicit an antibody response
A hapten is a small molecule that cannot independently elicit an antibody response; it must first attach to a larger carrier, usually a protein, forming a conjugate antigen. Antibodies made against that conjugate can then bind free hapten, showing recognition rather than independent initiation.
Worked example: A small drug-like molecule H alone fails to elicit antibodies in a test animal; after conjugation to carrier protein P, antibodies appear and later bind free circulating H, consistent with carrier-dependent sensitization.
Mistake to avoid: Calling free hapten incapable of antibody binding because it required a carrier to elicit the response.
Supporting reference: [16]
5. Fab recognition and Fc effector interactions
An antibody's two Fab arms terminate in variable regions whose amino acid sequence shapes the binding surface for a specific three-dimensional epitope. The Fc trunk, within the constant region, instead mediates effector recruitment, including complement factor binding and attachment of phagocytic cells during antibody-mediated opsonization. Recognition and effector recruitment are therefore distinct functions localized to different molecular regions.
Worked example: A laboratory fragment retaining only the variable-region arms binds the target epitope in a binding assay, yet this binding alone cannot demonstrate that complement fixation or phagocyte engagement through an intact Fc portion would occur in tissue.
Mistake to avoid: Attributing antigen specificity to the Fc region, or assuming that demonstrated epitope binding proves every Fc-dependent effector function remains intact.
Supporting reference: [16]
6. IgG transfer and IgA at mucosal surfaces
IgG is a monomer and the only antibody class able to cross the placental barrier, providing passive immunity to the developing fetus. Secretory IgA, assembled as a dimer, predominates in the mucus protecting mucous membranes and also appears in saliva, tears, and breast milk. This comparison concerns antibody distribution and function, not a diagnostic rule based on one measured concentration.
Worked example: A written vignette describing antibody-mediated protection within saliva points toward secretory IgA, whereas a question about antibodies reaching the fetal circulation during pregnancy identifies IgG as the class capable of placental transfer.
Mistake to avoid: Naming IgG, the most abundant serum antibody, as the class most associated with mucosal secretions instead of secretory IgA.
Supporting reference: [16]
7. Neutralization versus opsonization
Neutralization occurs when antibodies bind epitopes on pathogens or toxins, preventing their attachment to target cells. Opsonization instead coats a target so phagocytes can attach and ingest it; phagocytic cells carry surface receptors that recognize the Fc portion of IgG coating the organism. The same class, such as IgG, can contribute to either mechanism, so the described action must be classified by what the binding accomplishes.
Worked example: An antibody blocks a toxin from docking onto its target cell, illustrating neutralization; separately, an IgG-coated bacterium attaches to a macrophage through Fc receptors, illustrating opsonization rather than attachment blockade.
Mistake to avoid: Labeling every protective antibody interaction neutralization without first identifying whether the binding prevents attachment or promotes phagocyte ingestion.
Supporting reference: [16]
8. IgM architecture and agglutination
Secreted IgM assembles into a pentamer of five monomers joined by a J chain, yielding ten Fab binding sites per molecule. This multivalency makes it the most efficient antibody at cross-linking suspended targets into aggregates that filtering organs and phagocytes handle more readily. The monomeric, membrane-bound form serving as the B-cell receptor should not be described as pentameric.
Worked example: A teaching calculation counts five monomers times two Fab arms, giving ten binding sites on one secreted IgM pentamer; cross-linking several suspended particles into a visible clump demonstrates why this architecture favors agglutination.
Mistake to avoid: Transferring the pentameric description of secreted IgM to the monomeric membrane-bound B-cell receptor form on the cell surface.
Supporting reference: [16]
General neoplasia and diagnostic foundations
9. Desmoplasia is a stromal response
Desmoplasia describes proliferation of non-neoplastic connective tissue in association with a neoplasm, often producing a firm, scirrhous quality and distorting adjacent structures. The reactive fibrous stroma is induced by the tumor but is not itself neoplastic, so abundant fibrosis should not be misread as a separate connective-tissue malignancy or as proof that stromal cells form the neoplastic population.
Worked example: An oral squamous cell carcinoma biopsy shows invasive epithelial islands embedded in dense, pale collagen that the surgeon described as unusually hard. The collagen represents desmoplastic stroma produced in response to the carcinoma, not an independent fibrous neoplasm.
Mistake to avoid: Diagnosing a fibrosarcoma merely because desmoplastic collagen dominates the specimen, ignoring that reactive stroma lacks the features of a neoplastic proliferation.
Supporting reference: [13]
10. Angiogenesis supports continued tumor growth
Tumor cells elaborate growth factors that promote angiogenesis, and a neoplasm must establish a blood supply to sustain continued growth. This tumor-associated vascularity explains how enlarging lesions are nourished, but it does not by itself identify the tumor's lineage, distinguish benign from malignant, or confirm that the lesion arises from vascular cells.
Worked example: A progressively enlarging salivary gland tumor removed at surgery appears conspicuously vascular on its cut surface, with numerous thin-walled vessels at its periphery. These vessels reflect growth-factor-driven angiogenesis supporting expansion, not evidence that the tumor is of vascular origin.
Mistake to avoid: Calling a hypervascular neoplasm a hemangioma or angiosarcoma solely because abundant vessels surround and permeate the lesion.
Supporting reference: [13]
11. Necrosis can reflect unmet tumor demands
Necrosis in neoplasms is common because neoplastic cells function poorly and may fail to maintain their architecture, blood supply, or metabolic demands. The likelihood of necrosis increases as tumors enlarge and as differentiation decreases. These are tendencies rather than rules, so necrosis alone cannot establish tumor grade or prove a specific cause without correlation.
Worked example: A large, poorly differentiated carcinoma of the floor of the mouth shows central comedo-like necrosis with a rim of viable tumor at the periphery. Inadequate blood supply relative to the tumor's metabolic demands is a plausible explanation, pending correlation with clinical and histologic findings.
Mistake to avoid: Assigning a high grade automatically to any tumor containing necrosis, without additional cytologic, architectural, or clinical findings.
Supporting reference: [13]
12. Multiplicity suggests metastasis without proving it
Multiple masses within an organ usually indicate metastases, and metastatic deposits usually resemble the primary tumor morphologically, although neither rule is absolute. These observations support an interpretation of metastatic disease but do not independently establish the site of origin, which requires correlation of the clinical history, imaging distribution, and histologic findings.
Worked example: A patient with a known lung carcinoma develops several nodules in the liver that microscopically resemble the original tumor. Metastasis is strongly supported by multiplicity and morphologic similarity, but the interpretation still requires correlation with imaging and clinical findings.
Mistake to avoid: Dismissing metastasis because a hepatic deposit appears less differentiated than the primary tumor, since metastases do not always look identical.
Supporting reference: [13]
13. Morphology does not always predict behavior
Histologic or cytologic appearance alone may not settle whether a neoplasm behaves benignly or malignantly, because behavior may not correlate with appearance. When routine evaluation leaves the question unresolved, molecular studies may help clarify behavior, with testing chosen according to context rather than ordered routinely.
Worked example: A candidate reviews an intraoral tumor whose cytology appears deceptively bland, yet the lesion recurs and infiltrates bone; because morphology alone cannot resolve behavior, molecular studies may be needed to clarify the tumor's biologic behavior.
Mistake to avoid: Claiming that bland cytology guarantees benign behavior, or that a single molecular result replaces clinicopathologic assessment.
Supporting reference: [13]
14. Cell sampling and tissue sampling answer different questions
Cytologic methods, including fine-needle aspiration, sample cells from mass lesions, whereas biopsy samples small tissue pieces, and surgical pathology specimens can help determine a neoplasm's stage and grade. Staging may also incorporate clinical and imaging findings, so these specimen types are not interchangeable.
Worked example: An oral pathologist receives an FNA aspirate from a parotid mass showing epithelial cells, then a resection specimen; the aspirate supplied cells only, while the resection additionally permitted assessment of stage and grade.
Mistake to avoid: Assuming a cytology specimen automatically provides every feature that a full surgical specimen would allow assessment of.
15. Tumor markers have screening limitations
Serum tumor markers such as CEA, AFP, and HCG can contribute diagnostic information, but their sensitivity and specificity are imperfect. Applied as screening tests in a general population, they perform poorly, so an abnormal result warrants follow-up rather than a diagnosis, and a normal result cannot exclude malignancy by itself.
Worked example: A screening program checks an unselected adult population with a single serum marker; some healthy participants test positive and some patients with cancer test negative. The example resolves by showing that imperfect sensitivity and specificity make such markers unsuitable as general-population screening tools.
Mistake to avoid: Treating an abnormal serum marker as a definitive cancer diagnosis, or a normal marker as proof that no malignancy exists.
Supporting reference: [14]
16. Genetic susceptibility is different from cancer prediction
A positive genetic screening result, such as a cancer-predisposition gene defect, may suggest increased risk for some malignancies, but it does not predict if, when, or where a cancer will arise. Genetic findings therefore indicate susceptibility rather than a diagnosis, and they concern risk assessment rather than interpretation of a particular tumor's alterations.
Worked example: A patient with a documented BRCA-1-type predisposition finding but no diagnosed tumor asks whether cancer is certain. The case resolves by explaining that the result supports increased risk for some malignancies without predicting whether, when, or where a cancer will develop.
Mistake to avoid: Converting a susceptibility result into a diagnosis of an existing malignancy, or asserting that a specific cancer date is predictable.
Supporting reference: [14]
Oral mucosal disease and microbial diagnosis
17. Leukoplakia is a clinical diagnosis of exclusion
Leukoplakia is a clinical designation applied only after all other recognizable diseases have been excluded, including candidiasis, lichen planus, and leukoedema. The term is purely descriptive and carries no histopathological meaning; the lesion's significance depends on separate histological findings from biopsy.
Worked example: Assessment of a persistent white plaque on the lateral tongue finds no other recognizable clinical or pathological explanation after candidiasis, lichen planus, leukoedema, and other mimics are excluded; biopsy may still show only hyperkeratosis.
Mistake to avoid: Inferring epithelial dysplasia from the word leukoplakia, or using lesion persistence alone to establish the diagnosis.
Supporting reference: [5]
18. Erythroplakia carries a different pathological concern
Erythroplakia is encountered less often than leukoplakia, yet it is much more likely to be associated with epithelial dysplasia or carcinoma. Like leukoplakia, it is an exclusively clinical descriptor without specific histopathologic connotations, so the red appearance alone never establishes the diagnosis; microscopic examination of the tissue determines what the lesion actually represents.
Worked example: An unexplained red velvety patch on the floor of the mouth and a white patch on the buccal mucosa are both clinically designated lesions. The erythroplakic patch carries the stronger association with dysplasia or carcinoma, but only the biopsy findings can establish which diagnosis applies to either lesion.
Mistake to avoid: Assuming rarity equals low risk, so dismissing an erythroplakic patch as benign before histopathological examination has excluded dysplasia or carcinoma.
Supporting reference: [5]
19. Removable candidal plaques and their differential
Oropharyngeal candidiasis typically produces painless, creamy white, plaque-like lesions on the buccal mucosa, palate, gums, oropharynx, or tongue. Unlike the plaques of oral hairy leukoplakia, these candidal plaques can usually be scraped off with a tongue depressor. Removability is therefore a helpful differential feature within the overall presentation, not a universal rule for every white lesion.
Worked example: During examination of an immunosuppressed patient, creamy plaques on the buccal mucosa scrape off easily with a tongue depressor. This removability supports oropharyngeal candidiasis rather than oral hairy leukoplakia in the differential, though microscopic confirmation by potassium hydroxide preparation remains available when laboratory confirmation is required.
Mistake to avoid: Labeling every removable white lesion as candidiasis, or excluding candidal disease entirely simply because typical white plaques are absent clinically.
Supporting reference: [8]
20. Candidiasis can present without white plaques
Candidiasis does not always produce white plaques. Less commonly, erythematous patches without white plaques appear on the anterior or posterior upper palate or diffusely on the tongue, and Candida can also cause angular cheilosis. These appearances are compatible with candidal infection but are not specific to it, so candidiasis remains in the differential even without plaques.
Worked example: An immunosuppressed patient with a low CD4 count has diffuse erythema of the palate without any creamy plaques. The absence of white pseudomembranes does not remove oropharyngeal candidiasis from the differential, since erythematous candidal presentations are recognized, and angular cheilosis caused by Candida may accompany them.
Mistake to avoid: Treating white pseudomembranes as mandatory for diagnosing oral candidiasis, thereby overlooking erythematous palatal or lingual presentations and Candida-associated angular cheilosis.
Supporting reference: [8]
21. Microscopy, culture and commensal Candida
When laboratory confirmation is needed, potassium hydroxide preparations of scrapings can show characteristic yeast or hyphal forms, while culture of exudative material identifies the Candida species present. Because Candida commonly colonizes healthy mucosa as a commensal, isolation must be correlated with clinical findings.
Worked example: In an adult with HIV whose oral plaques look characteristic of candidiasis, KOH scraping demonstrates fungal forms and culture grows Candida albicans; microscopy confirms morphology while culture supplies species information.
Mistake to avoid: Equating Candida isolation from clinically healthy mucosa with symptomatic infection, without correlating laboratory results.
Supporting reference: [8]
22. Reticular and erosive oral lichen planus
Reticular oral lichen planus typically appears as slightly raised, lacy, web-like white threads, often on the cheeks. The erosive (atrophic) pattern often appears bright red from loss of the mucosa's top layer, causes discomfort when eating and drinking, and can ulcerate in severe cases.
Worked example: One patient has lacy, slightly raised white threads on the buccal mucosa, suggesting a reticular pattern; another has bright red, painful mucosa with surface loss, suggesting an erosive pattern, with diagnosis still requiring professional assessment.
Mistake to avoid: Assuming every presentation of oral lichen planus is painless or shares one uniform appearance.
Supporting reference: [9]
23. Lichenoid reactions require an exposure assessment
Lichenoid reactions can mimic lichen planus both clinically and microscopically, so an exposure assessment is essential. Potential triggers include medications, oral hygiene products such as flavored toothpastes, and occasionally metallic restorative materials. Identifying the underlying cause is often challenging, but when an agent is implicated and withdrawn under professional supervision, lesion resolution may follow; exposure history generates possibilities rather than proving causation.
Worked example: A patient develops white striae and red mucosa adjacent to a recently placed amalgam restoration. The clinician documents the temporal relationship and contact, considers a lichenoid reaction among differentials, and arranges specialist evaluation rather than labeling the lesion idiopathic lichen planus.
Mistake to avoid: Declaring an offending agent from microscopic resemblance alone, or advising patients to stop medications without their prescriber's supervision.
Supporting reference: [9]
Oral epithelial malignancy and disease extent
24. Oral cavity boundaries determine the applicable site
The oral cavity extends to the junction of the hard and soft palates above and the line of circumvallate papillae below, and includes the anterior two thirds of the tongue and the hard palate. Assign the anatomical site before applying oral cavity staging criteria.
Worked example: A biopsy confirms squamous cell carcinoma centered on the lateral border of the mobile tongue, anterior to the circumvallate papillae; the tumor is classified as an oral cavity cancer.
Mistake to avoid: Applying oral cavity criteria solely because a report uses the broad term tongue or lip.
Supporting reference: [5]
25. Invasion and differentiation describe different properties
Carcinoma in situ is the term applied when a carcinoma is noninvasive. An already-established invasive carcinoma can be well differentiated, moderately well differentiated, poorly differentiated, or undifferentiated, so a differentiation label alone does not establish whether invasion is present.
Worked example: An oral cavity pathology report states invasive, well differentiated carcinoma. The report explicitly establishes invasion and separately describes differentiation; the well differentiated label does not reverse the tumor's established invasive status into carcinoma in situ.
Mistake to avoid: Inferring either invasion or noninvasive status from a well differentiated label alone.
Supporting reference: [5]
26. Oral cavity T category combines size and depth of invasion
In the cited AJCC eighth-edition oral cavity criteria, clinical and pathological depth of invasion are used together with tumor size to determine the T category. DOI is depth of invasion and not tumor thickness, so the two measurements are not interchangeable when staging.
Worked example: Two oral cavity tumors each measure 1.8 cm. One has a confirmed DOI of 4 mm, meeting T1 criteria; the other has a confirmed DOI of 7 mm, meeting T2 criteria.
Mistake to avoid: Assigning the T category from diameter alone or entering a tumor-thickness measurement as DOI.
Supporting reference: [5]
27. Superficial gingival erosion is not sufficient for T4
Under the cited AJCC eighth-edition criteria, superficial erosion of bone or a tooth socket alone by a gingival primary is not sufficient to classify a tumor as T4. Other findings, such as size with DOI or invasion through cortical bone, may still qualify.
Worked example: A gingival carcinoma shows only superficial socket erosion around a healed extraction site. That isolated finding does not establish T4; the category still depends on tumor size, depth of invasion, and any other qualifying invasion findings.
Mistake to avoid: Treating any adjacent bone change as T4, or assuming absent cortical invasion excludes every T4 category.
Supporting reference: [5]
28. Midline proximity can produce bilateral lymphatic drainage
Oral cavity structures near the midline, such as the floor of mouth, frequently drain lymphatically to both sides of the neck through first-station nodes, including the submental, submandibular, buccinator, and jugulodigastric groups. This bilateral tendency means apparent lateralization of the visible primary does not exclude the possibility of contralateral nodal involvement.
Worked example: A floor-of-mouth carcinoma extends to within a few millimeters of the midline while appearing predominantly on the left; the examiner documents that contralateral submandibular and submental nodal basins warrant evaluation because midline proximity favors bilateral drainage, without asserting that metastasis is present.
Mistake to avoid: Concluding that a tumor sitting mostly on one side of the midline can drain only to ipsilateral cervical nodes.
Supporting reference: [5]
29. Margins and extranodal extension add prognostic information
A positive surgical margin significantly increases the risk of local recurrence, while extranodal extension in a metastatic lymph node is a significant adverse prognostic factor incorporated into the AJCC eighth edition. These findings concern different compartments, so each adds distinct prognostic information.
Worked example: A small anterior tongue carcinoma is resected with a positive margin, and a metastatic node shows extranodal extension. The margin raises local-recurrence concern, while the extranodal extension adds adverse prognostic information despite the small primary.
Mistake to avoid: Summarizing prognosis from the primary tumor's diameter alone while overlooking margin status and nodal extranodal extension.
Supporting reference: [5]
HPV testing in head and neck pathology
30. Oropharyngeal tissue testing and p16 positivity
CAP's 2025 update recommends high-risk HPV testing for all patients with newly diagnosed oropharyngeal squamous cell carcinoma, including all histologic subtypes. For oropharyngeal tissue specimens, p16 immunohistochemistry serves as the surrogate marker and is reported positive when there is at least 70% nuclear and cytoplasmic expression of at least moderate to strong intensity. HPV-associated oropharyngeal carcinomas should not receive a tumor grade or differentiation status.
Worked example: A tonsillar tissue specimen shows p16 staining in 85% of tumor cells, with moderate to strong nuclear and cytoplasmic expression. This meets the positivity threshold, so it is reported as positive and as a surrogate for high-risk HPV, without assigning a grade.
Mistake to avoid: Applying the 70% tissue cutoff to cytology or non-oropharyngeal specimens without considering the stated site and tissue setting.
Supporting reference: [15]
31. When p16 requires HPV-specific clarification
Even when p16 is indicated for oropharyngeal tissue, HPV-specific testing is required in defined situations: low-prevalence geographic regions, equivocal staining (50%–70%, or extensive but weak), discrepancy between staining and morphology, large multisite tumors overlapping the oropharynx, non-tonsillar non-base-of-tongue oropharyngeal sites, and clinical-trial requirements. Additional HPV-specific testing may also be performed at pathologist or clinician discretion.
Worked example: An oropharyngeal tissue specimen from a non-tonsillar, non-base-of-tongue site shows strong diffuse p16 staining. Because of the anatomical site, HPV-specific testing is indicated; the pathologist should not treat staining extent alone as sufficient in this setting.
Mistake to avoid: Interpreting p16 by staining percentage alone while ignoring intensity, morphology correlation, and the tumor's anatomical site.
Supporting reference: [15]
32. Oral cavity cancer has different routine HPV guidance
CAP advises pathologists not to routinely perform high-risk HPV testing for prognostic purposes on primary oral cavity, laryngeal, nasopharyngeal, or hypopharyngeal squamous carcinomas. This contrasts with newly diagnosed oropharyngeal squamous cell carcinoma, where testing is recommended for all patients. The restriction addresses routine prognostic testing, not every context-specific diagnostic investigation.
Worked example: A confirmed squamous cell carcinoma of the anterior tongue, an oral cavity subsite, is staged and reported. The oropharyngeal recommendation for universal prognostic HPV testing is not automatically transferred; routine prognostic testing is not advised, though context-specific diagnostic use remains possible.
Mistake to avoid: Treating the oral cavity and oropharynx as interchangeable sites and applying oropharyngeal HPV guidance to an oral cavity primary.
Supporting reference: [15]
33. Cervical nodal carcinoma of unknown primary
When metastatic squamous cell carcinoma appears in a cervical lymph node without an identified primary, CAP recommends routine high-risk HPV testing. For tissue specimens, pathologists may use p16 immunohistochemistry as a surrogate, but any p16-positive result must be followed by HPV-specific testing, and an explanatory note about a positive result is recommended.
Worked example: A cervical node biopsy shows metastatic squamous cell carcinoma, and no primary tumor is found despite clinical evaluation. The tissue is p16-positive, so HPV-specific testing is performed next, and the report includes a note explaining what a positive result signifies.
Mistake to avoid: Reporting p16 positivity as final in unknown-primary nodal tissue without confirmatory HPV-specific testing, thereby omitting the recommended second step.
Supporting reference: [15]
34. FNA specimens follow a distinct HPV testing pathway
For fine needle aspiration samples of nodal squamous cell carcinoma from patients with clinical findings suggesting an oropharyngeal or sinonasal primary, or with metastatic squamous carcinoma of unknown primary, CAP recommends HPV-specific testing. Selected circumstances permit p16 instead, and a negative FNA result should be reassessed by testing tissue if tissue later becomes available.
Worked example: A nodal FNA from metastatic squamous carcinoma of unknown primary tests HPV-negative. When a subsequent tissue specimen becomes available, the pathologist performs the recommended HPV testing on that tissue rather than treating the cytology result as final.
Mistake to avoid: Treating a negative HPV result on FNA as permanently conclusive and declining to test later tissue specimens when they become available.
Supporting reference: [15]
35. HPV assay selection requires appropriate performance and coverage
HPV-specific testing should employ assays with optimal performance characteristics, such as RNA in situ hybridization or DNA PCR, and adequate coverage of non-HPV16 high-risk types. CAP does not recommend DNA in situ hybridization. A method's name alone does not establish suitability; laboratories must confirm the assay actually performs well and covers the relevant types.
Worked example: A laboratory proposes an HPV assay that detects only HPV16. Even though HPV16 detection is technically reliable, the assay's failure to cover other high-risk types makes it unsuitable under the CAP recommendation.
Mistake to avoid: Assuming any test labeled HPV testing covers non-HPV16 high-risk types or satisfies the recommended performance characteristics.
Supporting reference: [15]
36. Sinonasal squamous carcinoma needs direct HPV assessment
CAP conditionally recommends routine high-risk HPV testing of sinonasal squamous cell carcinoma. Testing should directly assess transcriptionally active high-risk HPV using RNA in situ hybridization; p16 immunohistochemistry may screen tumors for confirmatory HPV-specific testing but does not replace it. This conditional recommendation applies specifically to sinonasal primaries, not to oropharyngeal pathways.
Worked example: A sinonasal squamous cell carcinoma shows strong p16 staining. The pathologist uses that result only as a screen and proceeds to RNA in situ hybridization to confirm transcriptionally active high-risk HPV, as the conditional recommendation directs.
Mistake to avoid: Applying the oropharyngeal p16 surrogate tissue pathway unchanged to a sinonasal primary instead of testing for transcriptionally active HPV.
Supporting reference: [15]
Salivary gland pathology
37. Major and minor salivary primaries use different staging frameworks
Tumors of the major salivary glands (parotid, submandibular, sublingual) are staged with gland-specific criteria based on size, extraparenchymal extension, nodal involvement, and metastasis. Tumors arising in minor salivary glands are instead staged according to the anatomical site of origin, such as the oral cavity or sinuses. A salivary histological diagnosis alone does not determine the applicable staging chapter; the tumor's location does.
Worked example: A carcinoma with salivary differentiation arises in a minor gland of the hard palate. Its oral cavity anatomical origin, rather than any major-gland framework, determines the staging criteria applied to this lesion.
Mistake to avoid: Applying parotid staging criteria to every tumor showing salivary differentiation, regardless of whether the primary arose in a major or a minor gland.
Supporting reference: [6]
38. An infiltrative margin supports salivary malignancy
Because benign and malignant salivary tumors can be difficult to separate, a key guiding principle for establishing malignant behavior is demonstration of an infiltrative margin. The margin should be interpreted together with the tumor's complete morphological and clinical context, and an unsampled margin is not itself proof of circumscription, so conclusions should remain appropriately qualified.
Worked example: A salivary tumor shows relatively bland cytology, but examination of the growth interface demonstrates infiltration into surrounding tissue. Interpreted in full context, that infiltrative margin supports malignant behavior despite the deceptively bland cellular appearance.
Mistake to avoid: Declaring a salivary tumor benign from cytological appearance alone while failing to evaluate the tumor's growth interface with adjacent tissue.
Supporting reference: [6]
39. Nerve symptoms raise concern, but painless masses can be malignant
Neurological signs such as numbness or weakness from nerve involvement typically indicate malignancy, and persistent facial pain is highly suggestive of it. However, most parotid tumors, both benign and malignant, present as asymptomatic masses. Symptoms therefore modify clinical concern: their absence does not exclude malignancy, and their presence does not identify a particular histological type.
Worked example: A patient has a painless parotid mass that remains diagnostically unresolved. Development of new facial weakness would increase concern for malignancy, but the absence of such symptoms cannot by itself establish that the mass is benign.
Mistake to avoid: Treating a painless swelling as a reliable benign-malignant separator, since many malignant parotid tumors also present as asymptomatic masses.
Supporting reference: [6]
40. Mucoepidermoid carcinoma contains a variable cellular mixture
Microscopically, mucoepidermoid carcinoma may combine mucus-producing cells, intermediate cells, and squamoid or epidermoid cells, but the relative amounts of these populations differ from one tumor to another. This morphologic variability aids diagnostic consideration, though the source discussion is an older morphology account and does not establish a current grading algorithm or molecular classification, so conclusions should remain appropriately qualified.
Worked example: A salivary gland biopsy contains abundant intermediate cells alongside smaller populations of mucus-secreting and squamoid cells. The uneven proportions still fit the described mixed cellular pattern and support consideration of mucoepidermoid carcinoma.
Mistake to avoid: Dismissing mucoepidermoid carcinoma because its mucus, intermediate and squamoid components are unevenly represented in the specimen.
Supporting reference: [11]
41. Adenoid cystic carcinoma has a different cellular organization
Adenoid cystic carcinoma is composed of epithelial and myoepithelial cells and may display architectural patterns that range from tubular to solid. This cellular organization contrasts with mucoepidermoid carcinoma, which combines mucus, intermediate, and squamoid or epidermoid cells. The comparison aids differential diagnosis of salivary tumors but does not by itself provide an exhaustive diagnostic or grading description of either entity.
Worked example: A biopsy of a minor salivary gland mass shows epithelial and myoepithelial cells arranged in both tubular and solid areas. Recognizing this dual cell population supports adenoid cystic carcinoma in the differential diagnosis rather than mucoepidermoid carcinoma.
Mistake to avoid: Demanding a single uniform growth pattern throughout the tumor before considering adenoid cystic carcinoma, despite its recognized pattern variability.
Supporting reference: [11]
42. Salivary tumor grade must be interpreted with stage
Histological grading of salivary gland carcinomas helps guide assessment, but the cited source notes it is not an independent indicator of clinical course and must be considered alongside clinical stage. Clinical stage, particularly tumor size, may be more important than grade for outcome. Grade therefore complements, and does not replace, staging information such as nerve involvement, fixation, or nodal and distant spread.
Worked example: A tumor board reviews a low-grade salivary carcinoma with fixation to deep structures and involved regional nodes. The low-grade label does not outweigh these findings; the reported outcome discussion integrates grade with the complete clinical stage.
Mistake to avoid: Predicting an individual patient's course from microscopic grade alone while ignoring clinical stage and anatomical extent of disease.
Supporting reference: [6]
43. Microscopic extension is not automatically extraparenchymal extension
Under the cited AJCC eighth-edition major salivary gland definitions, extraparenchymal extension means clinical or macroscopic evidence of invasion of soft tissues; microscopic evidence alone does not constitute extraparenchymal extension for classification purposes. Accordingly, a tumor sized within a given T category is not reclassified solely because microscopy shows invasion beyond the gland, though any other feature that establishes a higher category still applies.
Worked example: A major gland tumor measures 3 cm in greatest dimension. Clinically and macroscopically there is no soft-tissue invasion, although microscopy shows tumor cells extending into adjacent soft tissue. Under the cited criteria, the microscopic finding alone does not disqualify the T2 size-and-extension definition.
Mistake to avoid: Substituting any microscopic invasion outside gland tissue for the formal clinical or macroscopic staging definition of extraparenchymal extension.
Supporting reference: [6]
44. MRI contributes to salivary tumor localization
The cited summary states that, with excellent spatial resolution and superior soft-tissue contrast, MRI offers advantages over computed tomography for detecting and localizing head and neck tumors, and it is the preferred modality for evaluating suspected salivary gland neoplasms. Imaging may also contribute to staging, but it addresses localization and extent rather than replacing tissue-based histological diagnosis or overriding patient-specific imaging constraints.
Worked example: Before tissue sampling, a patient with a suspected parotid neoplasm undergoes MRI, which delineates the lesion's soft-tissue extent for the reported assessment. The imaging localizes and characterizes extent, while histological evaluation of obtained tissue remains the basis for the definitive diagnosis.
Mistake to avoid: Concluding that a preferred imaging modality establishes the histological diagnosis and makes tissue examination unnecessary.
Supporting reference: [6]
Jaw lesions and radiographic differentials
45. Ameloblastoma can be benign and locally aggressive
Ameloblastoma is one of the more common benign neoplasms of odontogenic origin. Despite its benign classification, it is a slow-growing, persistent neoplasm of odontogenic epithelial origin that behaves locally aggressively, and ameloblastomas tend to be clearly expansile. Benign here describes its classification, not an absence of local effects; this concept makes no claim about metastatic behavior.
Worked example: A jaw neoplasm biopsied as ameloblastoma has produced marked expansion over time. That persistent, clearly expansile local growth is compatible with the lesion's described benign odontogenic classification and locally aggressive behavior.
Mistake to avoid: Assuming a benign diagnosis means the lesion cannot expand substantially or behave aggressively at its primary site.
Supporting reference: [10]
46. A pericoronal unilocular appearance does not uniquely identify a cyst
Unicystic ameloblastoma can appear radiographically as a unilocular radiolucency associated with the crown of an impacted tooth. Because this lesion can present with exactly that appearance, a pericoronal unilocular pattern alone does not justify excluding unicystic ameloblastoma or establishing a simple cyst.
Worked example: A unilocular radiolucency surrounds the crown of an impacted molar on imaging. Unicystic ameloblastoma remains a possible explanation, because its described radiographic appearance includes this crown-associated unilocular pattern.
Mistake to avoid: Excluding unicystic ameloblastoma solely because the crown-associated unilocular radiolucency appears cyst-like.
Supporting reference: [10]
47. Histology can challenge a plausible jaw-lesion diagnosis
A corticated multilocular radiolucency, its location and the patient's age can all support placing ameloblastoma high on the differential diagnosis. However, discordant findings can weaken that interpretation: mild expansion is not typical, because ameloblastomas tend to be clearly expansile, and the histology may also fail to support the diagnosis. Radiographic plausibility therefore does not establish ameloblastoma, and limited expansion is not treated here as an absolute exclusion criterion.
Worked example: A referral labels a multilocular jaw lesion as suspected ameloblastoma, but the lesion's expansion is mild and the subsequent tissue interpretation does not support that diagnosis. The resolved conclusion is that the radiographic suspicion remains unconfirmed.
Mistake to avoid: Converting a plausible radiographic differential into a final ameloblastoma diagnosis while disregarding incompatible expansion and tissue findings.
Supporting reference: [10]
48. Cemento-ossifying fibroma: imaging and tissue findings
Imaging can aid assessment of cemento-ossifying fibroma and support surgical planning. Described CT findings include a well-circumscribed lucent target lesion with root divergence, while tissue typically shows generally hypercellular fibrous tissue with occasional bone islands or cementiform calcifications; these findings support consideration of the diagnosis.
Worked example: A circumscribed lucent jaw lesion separates two molar roots on CT, and tissue shows hypercellular fibrous stroma with bone islands; together these findings support consideration of cemento-ossifying fibroma.
Mistake to avoid: Treating mineralized calcification alone as definitive identification while overlooking the lesion's imaging and stromal findings.
Supporting reference: [12]
49. Cemento-ossifying fibroma planning depends on site and size
For cemento-ossifying fibroma, work-up can include CT to assist with diagnosis and surgical planning, and the surgical approach is dictated by anatomic location and tumor size, with resection approaches varying according to location and extent of disease. Specialist assessment determines the individual plan.
Worked example: Two confirmed cemento-ossifying fibromas share one diagnosis but differ greatly in jaw site and size; the shared name alone does not justify identical surgical plans, since location and extent guide specialist planning.
Mistake to avoid: Selecting a surgical approach from the diagnostic label alone without weighing location, size and extent.
Supporting reference: [12]
Systemic and hematolymphoid pathology
50. Indolent lymphoma is not synonymous with readily curable lymphoma
Indolent and aggressive describe tempo and histology, not curability. Indolent non-Hodgkin lymphoma may allow prolonged survival, yet it is usually not curable in advanced clinical stages, whereas aggressive lymphoma behaves worse in the short term but a significant number of patients can still be cured.
Worked example: Two patients receive lymphoma diagnoses that differ mainly in growth tempo; the slower-growing diagnosis cannot automatically be assigned the greater likelihood of cure, because advanced-stage indolent disease often remains incurable while some aggressive disease is curable.
Mistake to avoid: Using indolent as a synonym for benign, or aggressive as a synonym for incurable, when comparing lymphoma groups.
Supporting reference: [17]
51. Waldeyer ring involvement belongs within systemic lymphoma assessment
Non-Hodgkin lymphoma has a far greater tendency than Hodgkin lymphoma to spread to extranodal sites, and commonly involves noncontiguous lymph nodes, Waldeyer ring structures such as tonsils and adenoids, and other extranodal organs; therefore a head and neck presentation does not by itself represent disease confined to that region.
Worked example: Lymphoma is diagnosed in a tonsillar lesion within Waldeyer ring; that anatomical presentation alone does not determine whether disease is localized, because distribution must be established through the appropriate clinical staging evaluation.
Mistake to avoid: Inferring the entire systemic extent of lymphoma from the anatomical location of the first detected lesion alone.
Supporting reference: [17]
52. Marginal zone lymphoma terminology reflects its setting
Marginal zone lymphomas occur in nodal, extranodal and splenic forms: when they involve lymph nodes they are called nodal marginal zone B-cell lymphomas, when they involve extranodal sites they are called mucosa-associated lymphatic tissue (MALT) lymphomas, and splenic marginal zone lymphoma is a distinct clinical entity, so each site-associated name identifies a different clinical setting.
Worked example: A pathologically confirmed marginal zone lymphoma centered in a lymph node is described in the nodal category, rather than being automatically labeled a MALT lymphoma simply because marginal zone terminology sounds interchangeable across sites.
Mistake to avoid: Using MALT as an interchangeable name for every marginal zone lymphoma instead of matching terminology to the involved site.
Supporting reference: [17]
53. Lymphoma sampling must yield a sufficiently definite diagnosis
Both core needle and excisional biopsy can establish a lymphoma diagnosis, but sufficiency must be judged specimen by specimen. In a retrospective French cohort reviewed by experts, core biopsies yielded a definite diagnosis in 92.3% of cases and excisional biopsies in 98.1%, so neither method guarantees adequacy.
Worked example: A pathologist receives a core needle specimen from a cervical node and reports it insufficient for definite classification. Because this particular sample is uncertain, the team pursues further sampling rather than assuming the core method's usual success rate applies.
Mistake to avoid: Treating every core biopsy as inadequate, or assuming every excisional biopsy is automatically definitive without assessing the specimen.
Supporting reference: [17]
54. Gastric MALT associations do not establish oral treatment rules
Helicobacter pylori eradication may resolve localized gastric MALT lymphoma, whereas t(11;18) predicts poorer response to antibiotic therapy in that gastric setting. These relationships are site-specific; they qualify expectations about gastric disease and do not support infection-directed antibiotic treatment of oral or salivary MALT lymphoma.
Worked example: A patient with gastric MALT lymphoma tests positive for t(11;18). The finding tempers expectations for antibiotic response and prompts consideration of alternative approaches, while the team avoids concluding that eradication therapy must fail or that oral lesions require antibiotics.
Mistake to avoid: Transferring the stomach-specific Helicobacter treatment relationship to every extranodal MALT site, including oral and salivary presentations.
Supporting reference: [17]
Oral manifestations and treatment-related decisions
55. After transplantation, oral injury has competing explanations
After hematopoietic stem cell transplantation, oral mucosal injury may reflect chemotherapy-induced mucositis or acute oral graft-versus-host disease, and the two require differentiation using treatment and transplant history. Ongoing monitoring is also needed for chronic oral GVHD, potentially malignant mucosal disease, and oral squamous cell carcinoma.
Worked example: A transplant recipient develops painful oral ulceration during the early post-transplant period. The team reviews the conditioning regimen's timing and graft-versus-host disease risk factors before attributing the lesions, and schedules continued surveillance for chronic GVHD and malignant change rather than assuming routine mucositis.
Mistake to avoid: Labeling every post-transplant oral lesion as routine mucositis, or assuming chronic graft-versus-host disease surveillance is unnecessary.
Supporting reference: [7]
56. Oral hemorrhage reflects systemic and local factors
Oral hemorrhage during cancer therapy can arise from treatment-induced thrombocytopenia or coagulopathy, and preexisting gingivitis or periodontitis can compound bleeding even during routine hygiene. Management requires multidisciplinary attention to local measures, platelet count and function, and coagulation, with oversight individualized rather than tied to a single number.
Worked example: A patient receiving myelosuppressive chemotherapy has inflamed gingiva and new spontaneous oozing. The team considers both the local periodontal inflammation and the falling platelet count and coagulation status, coordinates local measures with the oncology team, and avoids attributing the bleeding to hygiene alone.
Mistake to avoid: Attributing oral bleeding exclusively to poor hygiene or exclusively to the platelet count without evaluating both factors.
Supporting reference: [7]
57. Disproportionate oral findings can signal hematologic relapse
In patients previously treated for leukemia or lymphoma, gingival infiltrates, oral infection, or bleeding exceeding what local pathology explains can suggest possible relapse; such findings warrant evaluation rather than dismissal as routine periodontal disease, but they do not independently establish relapse.
Worked example: A man treated for lymphoma develops gingival bleeding far exceeding his mild plaque-related inflammation; the clinician documents the disproportion and refers him for hematologic assessment rather than attributing everything to local disease.
Mistake to avoid: Treating disproportionate gingival bleeding as ordinary gingivitis, or asserting relapse before confirmatory hematologic evaluation is completed.
Supporting reference: [7]
58. Cancer-related dysgeusia is multifactorial
Taste disturbance during chemotherapy or head and neck radiation can arise from several contributing mechanisms, including direct neurotoxicity to taste buds, impaired taste-cell regeneration, xerostomia, infection, psychological conditioning, and graft-versus-host disease injury. The dominant mechanism and the recovery course vary by treatment modality and individual patient context, so no single cause should be assumed.
Worked example: A woman receiving chemotherapy reports metallic taste and dry mouth. Her clinician explains that xerostomia, drug effects, and altered taste-cell regeneration may each contribute, and that taste often improves over ensuing months, without promising an exact recovery date.
Mistake to avoid: Blaming every taste complaint solely on xerostomia, or telling patients their taste will recover on a fixed schedule.
Supporting reference: [7]
59. Elective jaw surgery during oncologic bone-modifying therapy
Elective dentoalveolar procedures such as medically unnecessary extractions, alveoplasties, and implants should generally be avoided while a patient is on active bone-modifying agent therapy at an oncologic dose. Exceptions require review of benefits and risks by a dental specialist experienced in MRONJ prevention and treatment, together with the patient and oncology team. If surgery proceeds, frequent follow-up continues until full mucosal coverage.
Worked example: A patient on oncologic-dose denosumab requests an elective implant. The dentist explains that such procedures are generally deferred during active therapy and that any exception would need documented benefit-risk review with an MRONJ-experienced specialist and the oncology team.
Mistake to avoid: Stating that all dental treatment is banned during therapy, or discussing exceptions without naming the oncologic dose setting.
Supporting reference: [7]
60. A bone-modifying drug holiday is not an established universal solution
For patients with cancer receiving a bone-modifying agent at an oncologic dose, the available evidence is insufficient to support or refute discontinuing the medication before dentoalveolar surgery. Any deferral of administration rests with the treating physician, decided in consultation with the patient and oral health provider, and no fixed interruption interval or guaranteed risk reduction is established.
Worked example: A patient scheduled for a necessary extraction asks whether pausing her bone-modifying agent for a set period will guarantee the surgery is safe. The clinician explains that evidence neither supports nor refutes discontinuation and that any deferral is her oncologist's decision.
Mistake to avoid: Recommending a standard three-month drug holiday, or advising the patient to stop medication independently before surgery.
Supporting reference: [7]
Sources and official outline
- AAOMP 2026 Guidelines for the Fellowship Examination
- AAOMP 2026 Fellowship Examination
- ABOMP Application for Initial Certification
- ABOMP Bylaws and Policies
- NCI Lip and Oral Cavity Cancer Treatment (PDQ)
- NCI Salivary Gland Cancer Treatment (PDQ)
- NCI Oral Complications of Cancer Therapies (PDQ)
- NIH Candidiasis: Mucocutaneous Opportunistic Infections
- American Academy of Oral Medicine: Oral Lichen Planus
- University of Washington March 2011 Diagnostic Discussion
- UC Davis Pathology May 2016: Low-Grade Mucoepidermoid Carcinoma
- UC Davis Pathology December 2015: Cemento-Ossifying Fibroma
- University of Utah WebPath: Morphologic Appearances of Neoplasms
- University of Utah WebPath: Diagnosis of Neoplasia
- College of American Pathologists: HPV Testing in Head and Neck Carcinomas
- OpenStax Microbiology: Specific Adaptive Immunity
- NCI Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ)